DaVita Inc.（DVA） · Hospital Operations

DaVita In-Depth Value Investing Research

May 30, 2026·~21 min read

Quick ReadPlain-language overview · read this first

DaVita operates about 2,657 outpatient dialysis centers in the United States, serving about 200,000 end-stage renal disease patients, and is one of the dialysis duopoly alongside Fresenius. Dialysis is an inelastic, life-sustaining service, with extremely stable demand but very low industry growth—more of an excellent company in a difficult industry. This business's real vulnerability lies not in demand but in its profit source: commercial-insurance patients account for only about 11% yet contribute nearly all profit, and once the payment structure is reshaped, the entire valuation framework shifts down.

The analyst assigns a Watch rating, the core reason being that quality is solid but the margin of safety is insufficient. The cash flow is real, with trailing-twelve-month free cash flow of about $1.2 billion, long above accounting net income; management has done aggressive buybacks around per-share value for years, shrinking the share count by about 30% in a little over three years. The cost is a balance sheet that has lost its hard safety cushion—book equity is already negative, goodwill exceeds 40% of total assets, and net debt/EBITDA is above 3.3x, leaving little book backstop if the investment fails.

Discounting conservative owner earnings, the analyst gives three intrinsic-value tiers: conservative $170-190, neutral $220-260, optimistic $280-320. The current roughly $194 sits between the top of the conservative range and the neutral range, and is not cheap for relatively conservative capital. The ideal buy range is $150-170, corresponding to a thicker cash-flow yield and compensation for payment/leverage risk. If the commercial-payment share, unit price, or cash-flow conversion keeps deteriorating, or net leverage breaks above 4x, this business must be re-evaluated.

Lead
The leading U.S. dialysis-center chain for end-stage renal disease, with inelastic demand, strong cash flow, and outstanding buyback execution, yet nearly all of its profit depends on high-priced commercial insurance while it carries negative book equity and net leverage above 3x. At roughly $194 the stock sits between the conservative and neutral valuations, leaving too thin a margin of safety. We assign a Watch rating, with an ideal buy range of $150-170.

Full report

Prices in the article are as of publication; see the valuation band above for the live price.

Conclusion First

I will try to sort the content into four categories: Facts (drawn directly from the company, the SEC, regulators, or official market data), Assumptions (valuation parameters), Inferences (derived from facts and assumptions), and Opinions (the final investment judgment).

Item	Assessment
Investment rating	Watch
Core judgment	The business is understandable, cash flow is strong, and buyback execution is very disciplined, but profit depends heavily on high-priced commercial insurance, leverage is not low, and the balance sheet lacks a "hard safety cushion," so the current price is not cheap for a relatively conservative long-term investor.
Does the current price offer a margin of safety	Not obvious
Suitable investors	Long-term value investors who can accept regulatory/payer risk, understand the healthcare payment system, and favor high cash flow and buybacks
Biggest uncertainty	The share of commercial-insurance patients and their unit price, changes in the regulatory/legal environment, and the ability to maintain moderate leverage amid an aggressive buyback pace

As of May 29, 2026, DVA traded at roughly $194.36, with a market cap of about $13.39 billion and a trailing P/E the market assigns of about 18.1x. At the end of Q1 2026 the company had 66.2 million shares outstanding, having shrunk its share count materially through large-scale buybacks over the past few years. On the company's disclosed basis, trailing-twelve-month free cash flow was about $1.209 billion; on a more conservative basis closer to "owner earnings," equity-level owner earnings run roughly between $1.21 billion and $1.33 billion, so the current share price corresponds to about 10-11x owner earnings / FCF. That does not look expensive, but it is not cheap enough to ignore payer and policy risk.

My preliminary conclusion: DaVita looks more like a "high-quality but not clean" cash-flow business. Its demand is very stable, industry entry barriers are not low, and its operating capability and capital allocation are both solid; but its excess profit comes from the payment structure unique to the U.S. dialysis industry—especially the cross-subsidy that high-priced commercial insurance provides to the Medicare system—rather than from an unassailable brand or network effect. In its own risk disclosures the company states plainly that payments from commercial payers contribute nearly all of its profit, and that all non-acute dialysis profit comes from commercial payers. This means that if the commercial-patient mix, payment duration, or payment rates were revised down systematically, both the valuation and the investment logic would have to be rewritten.

If your risk appetite is "balanced-leaning-conservative," I would rather place DVA on a high-quality watch list than buy a heavy position today. The more ideal entry point is roughly the $150-170 range; if you already hold it, as long as the commercial payment structure, leverage, and cash-flow conversion do not deteriorate meaningfully, I lean toward continuing to hold rather than simply selling.

Business Understanding and Industry Landscape

DaVita's core business is essentially simple: providing the life-sustaining dialysis treatment that end-stage renal disease (ESRD) patients require, with lab services, in-hospital dialysis, home dialysis, international dialysis, and integrated kidney care risk-based management services for chronic kidney disease and ESRD patients built around that core. At the end of 2025 the company served about 200,500 dialysis patients in the United States and operated 2,657 outpatient dialysis centers there; its international business had 585 centers in 14 countries serving about 94,500 patients; and as of the end of 2025, DaVita IKC also served about 66,000 risk-based patients and 9,400 other integrated-care patients. By March 31, 2026, the company served about 296,300 patients worldwide across 3,262 facilities, of which 2,666 were in the United States.

This demand is very stable, because once ESRD reaches the dialysis stage, dialysis is typically a "continuous, inelastic, life-sustaining" service; the company's 10-K also states plainly that once kidney function fails it is generally irreversible, and patients need ongoing dialysis or a kidney transplant to survive. The United States Renal Data System shows about 557,000 dialysis patients in the U.S. in 2023; but on the other hand, patient growth has clearly slowed. The USRDS data the company cites show a U.S. dialysis-patient CAGR of about 1.8% over 2013-2023, but only about 0.2% over 2018-2023. This is not a high-growth arena but a mature, stable, low-growth essential-healthcare industry.

Looking at the revenue mix, how DaVita "makes its money" is also clear. In 2025 about 86% of consolidated revenue came from the U.S. dialysis business. Within U.S. dialysis patient service revenue, Medicare and Medicare Advantage account for 57%, Medicaid for 7%, and other government programs for 3%, for 68% government payment in total; commercial insurance and hospital dialysis services account for 32%. But the profit structure matters more: the company discloses that non-hospital commercial payers correspond to about 11% of U.S. dialysis patients yet contribute about 26% of U.S. dialysis patient service revenue, and that nearly all profit—and all non-acute dialysis profit—comes from commercial payers. This sentence is one of the most important facts in the entire investment analysis.

So this business has two layers of revenue stability. The first layer—treatment demand itself—is very stable. The second layer—unit economics—is not as stable as it looks, because the U.S. government's dialysis payment rates are rule-based and bundled, and commercial payment prices are the variable that truly determines profit elasticity. The Medicare ESRD PPS uses a bundled payment, with a fixed payment covering the vast majority of dialysis-related drugs, services, and lab items; CMS raised the ESRD PPS base rate to $281.71 in 2026, expected to lift total payments to ESRD facilities by about 2.2%. That provides some tailwind, but it does not mean the company holds genuine free pricing power.

The cost structure is also easy to understand: it is a labor-intensive, supply-chain- and compliance-intensive healthcare-services business. The company discloses that the main drivers of U.S. dialysis patient-care costs include clinical labor hours and wages/benefits, the purchase prices and usage of pharmaceuticals and medical supplies, and facility infrastructure costs. It also states plainly in its risk factors that the business is sensitive to shortages of nurses and other clinical staff, wage increases, and supply-price fluctuations. In other words, this is not a SaaS-style asset-light business, nor a branded consumer product; it is a high-turnover, highly regulated, execution-intensive healthcare-services network.

On the competitive landscape, U.S. outpatient dialysis is a highly concentrated industry. In 2022 DaVita estimated it held about 36% of the U.S. dialysis market by patient count; in its 10-K the company explicitly names Fresenius Medical Care as its largest competitor, noting that Fresenius also owns dialysis-equipment and supply manufacturing, giving it a vertical-integration advantage. In Q1 2026 Fresenius disclosed 3,539 dialysis clinics worldwide serving about 289,923 patients; it completed about 44 million dialysis treatments in 2025, while continuing to advance value-based care and the 5008X device rollout. For DaVita, this shows the market is not fragmented competition but primarily a duopoly, with regional players secondary.

My judgment: this is "a business I can understand," but not "a naturally beautiful industry." Demand is stable and business transparency is above average, but profit is deeply affected by the payer and policy structure, so it is more of an "excellent company in a difficult industry" than an "easy king in a good industry." If the stock market closed for five years I would be willing to hold this business—provided I bought in with a better margin of safety. Business understandability score: 4/5. Industry attractiveness score: 3/5.

Moat

DaVita's moat does not rest on a consumer brand or on network effects. It looks more like a "composite moat" formed by the layering of scale, regulation, local switching costs, and operating capability. First, what it lacks: its brand advantage is limited—end patients will not pay a premium out of brand preference the way they buy Coke; network effects are almost nonexistent; and while a data advantage does exist in clinical and payment management, it is not enough on its own to constitute a non-replicable moat.

The truly effective moat comes first from scale advantage. DaVita has a vast facility network, clinical processes, physician relationships, and payer-contract system in the United States; U.S. dialysis revenue reached $11.793 billion in 2025, and by Q1 2026 it served close to 300,000 patients worldwide. This lets it better amortize back-office administration, IT, procurement, and compliance costs, and hold a stronger position when negotiating with payers and hospital systems. The company itself emphasizes that U.S. dialysis is its largest business and that it has built "a robust platform and nephrologist and payer relationships."

The second layer of the moat comes from regulatory and licensing barriers. To participate in the Medicare ESRD program, a dialysis center must meet qualification requirements, accept regulation, and be overseen by a medical director; in some states, opening, relocating, or adding a facility requires additional state licenses or a certificate-of-need. For a new entrant, replicating a nationwide facility network, payment contracts, and medical-director and nephrologist relationships is by no means something that can be done quickly or with low capital spending.

The third layer of the moat is a degree of switching cost, though not software-style "lock-in." Dialysis patients typically need multiple treatments per week, and distance from home, treatment time slots, physician collaboration, referral relationships, insurance-network coverage, compliance records, and clinical continuity all affect whether a patient moves, so patients and physicians do not switch providers frequently or lightly. Yet this switching cost is not enough to let the company raise prices at will, because the strongest constraint comes from payers, not patients.

The fourth layer of the moat is operating capability and corporate culture. DaVita has long emphasized clinical quality, process-driven management, and team culture; the company says it has led the industry in CMS's five-star quality system for the last 11 reportable years. Although such statements carry the company's own framing, they do show it is not an asset-piling operator that "only earns money off industry tailwinds," but one with a full set of processes, standardization, and incentive mechanisms supporting facility operations. After the 2025 cybersecurity incident, the company still delivered full-year $2.094 billion in adjusted operating income and $1.024 billion in free cash flow, and in Q1 2026 continued to achieve a $1.40 billion annualized run-rate of free cash flow—results that indirectly corroborate its operating resilience.

But I want to be very clear: DaVita's moat is not a "pricing-power moat" but an "entry-and-execution moat." In an inflationary environment, the company cannot proactively raise prices the way a luxury or software business can; it depends far more on Medicare rule updates, commercial-contract negotiations, patient mix, and cost control. The 10-K states plainly that commercial payment rates face continual downward pressure, and that a decline in commercial-patient coverage would materially and adversely affect the business. In a downturn, dialysis demand persists, but margins are not necessarily stable, because commercial-insurance coverage may deteriorate due to unemployment, benefit-design changes, or legal-environment changes.

On balance, I think DaVita's moat exists but is not perfect: Brand advantage: weak; cost advantage: moderate; scale advantage: strong; network effects: weak; switching costs: moderate; channel and physician relationships: moderate-to-strong; regulatory barriers: strong; data advantage: moderate; corporate culture and execution: moderate-to-strong; capital-allocation capability: strong. My conclusion: the moat is overall "stable but narrow," and it is not clearly widening. If the commercial payment environment holds, competitors will find it hard to replicate with modest capital; but if the legal/payment structure reallocates the profit pool, the moat will immediately look far less deep. Moat strength score: 3/5.

Management and Capital Allocation

On management, my assessment of DaVita is "trustworthy overall, but you must keep a constant eye on its buyback discipline and leverage limits." As of March 31, 2026, CEO Javier Rodriguez held about 845,144 shares, roughly 1.3% of the company; Berkshire Hathaway and Warren Buffett-related entities held about 30.1 million shares, corresponding to a 45.5% stake. The company has senior-management stock-ownership guidelines, a clear clawback mechanism, and an equity-incentive structure oriented toward performance and relative shareholder returns. The 2025 say-on-pay vote received about 94% support. Overall, the governance and incentive framework leans shareholder-oriented.

The incentive design is also reasonable. The company discloses that 2025 long-term incentives were broadly composed of 60% PSUs, 20% RSUs, and 20% SSARs, with the PSUs assessed mainly on three-year cumulative adjusted EPS and relative TSR. The advantage of this structure is that it truly focuses executives' attention on per-share value growth rather than on sheer revenue scale or facility count. The drawback: an EPS orientation naturally encourages buybacks, and when the company is highly levered and in negative-equity territory, excessive buybacks amplify the asymmetry between reward and risk.

DaVita's capital-allocation core can be captured in almost one word: buybacks. In 2025 the company repurchased 12.679 million shares for about $1.788 billion, at an average price of about $140.09/share; of that, 9.292 million shares were bought in the open market and another 3.387 million shares from Berkshire. In 2024 it repurchased 9.833 million shares for $1.389 billion; in Q1 2026 it repurchased another 3.0 million shares for $403 million, and after quarter-end, through May 5, it repurchased an additional 2.0 million shares for $302 million. From about 96.3 million shares in January 2022 to about 66.8 million shares in February 2026, the company shrank its share count by roughly 30.6%. This is very aggressive—and very effective—per-share capital allocation.

By results, these buybacks created value. The company pays no dividend, and shareholder returns are delivered almost entirely through buybacks; DVA has repurchased heavily over the past few years roughly in the $100-156 range, and its long-run average buyback multiple is not outrageous. In particular, the 2022-2023 buyback price of about $97-98/share was clearly better than the current level. From a "results-oriented" view of capital allocation, these buybacks were quite good.

But two flaws that a conservative investor cannot ignore must be pointed out. First, the Berkshire buyback agreement requires the company to repurchase enough shares each quarter to bring Berkshire's stake back to 45% whenever it exceeds 45%. This mechanically routes part of the company's buybacks "automatically to Berkshire." By the end of Q1 2026, the company had recorded a buyback obligation to Berkshire of $86.5 million, and when settlement was completed on May 1, 2026, the total rose to $182.9 million at an average price of $149.84/share. This is not a bad thing, but it means buybacks are not entirely at management's free discretion to time in the secondary market. Second, the company maintained strong buybacks in 2025, producing a total equity deficit of $476 million and a shareholders'-equity deficit attributable to the company of $755 million on the books by Q1 2026. That weakens the balance sheet's margin for error.

Overall, I give management and capital allocation a positive but not blind assessment. They have honestly disclosed the fragility of the profit source, the buyback terms, and the legal and payment risks, and they have genuinely stuck with a per-share orientation over the long run; but for a relatively conservative investor, their preference for buybacks sometimes approaches "overuse." Management and capital-allocation score: 4/5.

Financial Quality and Owner Earnings

First, a key financial table. In the table below, revenue, net income attributable to the company, operating cash flow, and weighted diluted share count come mainly from the company's 10-K/10-Q; where an item is "calculated by the author," I state the basis directly.

Year	Revenue	Net income attributable	Operating cash flow	Diluted shares	Notes
2021	$11.619 billion	$978 million	$1.931 billion	109.9 million	Solid operating performance
2022	$11.610 billion	$560 million	$1.565 billion	95.8 million	Profit clearly under pressure
2023	$12.140 billion	$692 million	$2.059 billion	93.2 million	Cash flow rebounded
2024	$12.816 billion	$936 million	$2.022 billion	87.3 million	Profit recovered
2025	$13.643 billion	$747 million	$1.887 billion	75.9 million	Affected by cybersecurity and other factors
TTM to 2026Q1	$13.835 billion	$781 million	$2.027 billion	~68.9 million	Calculated as full-year 2025 plus 2026Q1 minus 2025Q1

Revenue, net income attributable, operating cash flow, and diluted shares in the table come from the company's 2021-2025 10-Ks and its 2026Q1 10-Q/earnings release; the "trailing-twelve-month" row is a direct rolling calculation from the company's disclosed data.

This table yields several important conclusions. First, revenue growth is not fast. From 2021 to 2025 revenue grew from $11.619 billion to $13.643 billion, a four-year CAGR of roughly 4%, matching the mature-industry profile it sits in. Second, profit is more volatile than revenue. Net income attributable fell clearly in 2022, recovered clearly in 2024, and slipped again in 2025. For this kind of company, short-term EPS matters far less than cash flow. Third, operating cash flow has long exceeded net income attributable, showing that although the income statement is affected by estimates and non-cash items, this business's cash-generating ability is genuinely real.

If you look only at margins, DaVita is not bad either. On an aggregated segment-operating-income basis, operating margin fell roughly from about 15.5% in 2021 to about 11.5% in 2022, then recovered to about 16.3% in 2024 and about 15.0% in 2025; the quarterly operating margin the company disclosed for Q1 2026 was about 14.1%. The issue is not the absolute margin level but its sustainability—because what supports the high margin is not free pricing but the U.S. commercial payment structure and strict cost control.

On cash-flow quality, the company's disclosed free cash flow was $1.024 billion in 2025 and $1.162 billion in 2024; for the trailing twelve months to Q1 2026, free cash flow was $1.209 billion. Using net income attributable as the denominator, the 2025 FCF conversion rate was about 137% and 2024's about 124%. This shows DaVita's "true earnings" are at times even better than its accounting net income, not worse. For a healthcare-services company that needs ongoing facility capex, that is a strong performance.

But financial quality is not without red flags. In 2025 the company's operating cash flow was dragged down by other working-capital changes of -$230 million; as of the end of 2025, the portion of U.S. dialysis receivables aged more than six months still made up 18%, improved from 23% in 2024 but still not small; and contract assets and receivables related to Medicare bad-debt claims awaiting approval were about $132 million, up from $107 million in 2024. This means the company does have estimation risk—it just does not appear to be out of control yet.

The balance sheet is where a relatively conservative investor should be most critical. By March 31, 2026, total assets were about $17.499 billion and total liabilities about $16.451 billion, for total liabilities/total assets of about 94%; long-term debt was $10.514 billion, and adding $113 million of debt due within one year brings total debt principal to about $10.694 billion. On the basis its credit agreement uses, the company disclosed net debt of about $10.031 billion and trailing-twelve-month EBITDA of about $3.008 billion, for net debt/EBITDA of 3.34x; the weighted-average blended interest rate over the period was about 5.44%. Roughly computed from TTM operating income of $2.087 billion and interest expense of $535 million, interest coverage is about 3.9x. This is not dangerous enough to panic about, but it is by no means a "carefree" balance sheet.

More noteworthy is that DaVita's book shareholders' equity has already turned negative due to long-running large buybacks: the Q1 2026 shareholders'-equity deficit attributable to the company was about $755 million, and the total equity deficit about $476 million; meanwhile the company carries goodwill of about $7.582 billion, about 43% of total assets. This has two effects: first, ROE and P/B are essentially distorted and carry almost no analytical meaning; second, the company lacks downside protection from asset-liquidation value. So buying DVA is not buying a discount to net assets, but buying the discounted present value of many years of future cash flow.

On an "owner earnings" basis, I offer two levels of estimate. Level one, a strictly conservative basis: directly use the company's trailing-twelve-month free cash flow of $1.209 billion, without adding back "development capex." This is the most conservative and least-likely-to-overstate owner-earnings approximation. Level two, an equity owner-earnings figure closer to the Buffett-style definition: take trailing-twelve-month operating cash flow of $2.027 billion, subtract maintenance capex of $391 million, then deduct distributions to non-controlling shareholders of $317 million, and add back non-controlling-shareholder contributions of $9 million, to get about $1.328 billion. Because the company reports development capex separately, I lean toward viewing at least part of it as growth investment rather than pure maintenance spending. To be conservative, in the valuation section below I use the lower $1.21 billion as baseline owner earnings.

Based on the current market cap of $13.39 billion, DVA corresponds to roughly: about 11.1x trailing-twelve-month free cash flow; about 10.1-11.1x conservative owner earnings; about 7.8x EV/EBITDA; P/B not applicable, because book value is already negative. This set of multiples shows the company is not expensive, but given its fragile profit source, negative equity, and leverage above 3x, it is no "cigar butt" either.

Valuation and Margin of Safety

Method 1: owner-earnings discount. I use the conservative owner-earnings figure of $1.21 billion as the starting point, rather than the more aggressive $1.33 billion; I do this because I do not want to assume that all development capex is "fully avoidable" growth spending. I then run three scenarios: Conservative scenario: owner earnings grow 1% annually over the next 10 years, discounted at 10%, with a terminal value of 9x owner earnings; Neutral scenario: annual growth of 3% over the next 10 years, discounted at 9%, terminal value 11x owner earnings; Optimistic scenario: annual growth of 4.5% over the next 10 years, discounted at 8.5%, terminal value 12x owner earnings. Under these assumptions, I estimate per-share intrinsic value roughly at: conservative $170-190, neutral $220-260, optimistic $280-320. Because the share count may be further reduced by future buybacks, this range is not pessimistic; at the same time, it does not assume a high-multiple re-rating as a premise. This valuation is an inference, not a fact.

Method 2: relative valuation. DVA's current trailing P/E is about 18.1x, its trailing-twelve-month FCF multiple about 11.1x, and EV/EBITDA about 7.8x. On cash-flow multiples, DVA is not expensive; on accounting-earnings multiples, it is not outrageously cheap either. Fresenius Medical Care, as the largest peer, delivered €19.628 billion in revenue, €2.212 billion in adjusted operating income, and €3.327 billion in EBITDA in 2025, with Q1 2026 net leverage of 2.6x, about 290,000 patients worldwide, and 3,539 clinics—showing that peers likewise rely on scale, payment structure, and efficiency gains. Because FMS uses IFRS and involves ADR/local-currency and exchange-rate issues, I will not force a "seemingly precise but actually misleading" cross-currency P/E or P/FCF here; but I will state the conclusion clearly: DVA's cash-flow multiple is not much higher than its business quality warrants—the problem is that its risk premium is not low either.

Method 3: asset or liquidation value. This method is unfriendly to DVA. The company is not a net-cash company but a high-debt, high-goodwill, negative-equity one. By 2026Q1, goodwill of $7.582 billion made up about 43% of total assets, and total equity was negative; on top of that there is large long-term debt, operating leases, and minority-shareholder put obligations. In other words, book value is not a safety cushion—it would instead mislead the analysis. If one insists on using this method, the only conclusion is: DVA's valuation must be built on going-concern and future cash flow, not on liquidation value.

Putting the three methods together, my range judgment is: Conservative intrinsic-value range: $170-190/share; Fair intrinsic-value range: $220-260/share; Optimistic intrinsic-value range: $280-320/share. At the current $194.36, it is roughly 12%-25% below my neutral range, but slightly above the top of my conservative range, or only close to it. So whether it is "cheap" depends on the margin-of-safety standard you require; for relatively conservative capital, my answer is: not yet enough.

My price discipline is a bit more explicit: Ideal buy range: $150-170. This roughly corresponds to a further 25%-35% discount to my "fair value" center, and usually falls around 8-9x conservative owner earnings. Acceptable holding range: $170-220. This means if you already hold, there is no rush to sell; but new buying should be more selective. Clearly overvalued range: above $260. Once in this zone, investment returns depend more on continued market optimism than on organic cash flow.

The most fragile assumption behind the margin of safety is that the commercial-payer structure is not reshaped. If growth is below expectations and margins dip slightly, the investment case may still hold; but if the commercial-patient share, payment duration, or payment rates are revised down structurally, DVA's owner earnings may not just "earn a bit less"—the profit pool would be repriced. I pay particular attention to the 10-K's language on commercial-plan design changes after the Marietta case, commercial-insurance restrictions, and limits on charitable premium assistance, because these all directly hit the key stratum of "that 11% of patients, 26% of revenue, nearly all profit."

So DVA now looks more like "a good company at only an average price" than "a good company at a bad price" or "a bad company cheap enough to be worth picking up." It is worth waiting for a better price.

Risks, Comparison, and Final Judgment

The most important risk is not short-term volatility but the sources of permanent capital loss. First is payer and regulatory risk: if the commercial payment environment deteriorates due to law, plan design, employer-insurance trends, or Medicaid/Medicare policy changes, profit will be compressed directly. Second is financial-leverage risk: although current leverage is still in a manageable range and the credit agreement permits maximum leverage up to 5.0x, net leverage above 3.3x combined with negative equity does not allow much room for error. Third is cost risk: labor shortages, wage increases, and rising purchase prices for drugs and supplies would all erode per-unit profit under bundled payment. Fourth is operating and compliance risk: although the 2025 cybersecurity incident only produced an adjustment of about $25 million, it reminds us this is a company heavily dependent on IT, billing systems, and sensitive medical data. Fifth is accounting and receivables risk: the company's revenue recognition depends significantly on judgments about commercial contracts, Medicare/Medicaid estimates, and bad-debt recovery, and receivables and contract assets are sizable.

The strongest bear case, I think, runs like this: DaVita looks like a high-cash-flow monopoly, but it essentially earns its money off a "high-margin enclave" within the U.S. healthcare payment system; once that enclave shrinks, the entire valuation framework shifts down. What bears really see is not demand disappearing, but that the company's most profitable revenue is overly concentrated in commercial payers rather than in more stable, predictable government payment. The company itself admits that commercial payers contribute nearly all of its profit. For this kind of company, the common investor mistake is not overestimating demand but overestimating the steady-state stability of the profit structure.

Which facts would overturn the investment judgment? I would watch the following: if the commercial-insurance patient share, payment duration, or average realized unit price in the U.S. dialysis business declines clearly for several consecutive quarters; if trailing-twelve-month owner earnings keep falling below $900 million with no recovery in sight; if net debt/EBITDA rises above 4x alongside rising refinancing costs; if longer-aged receivables, contract assets, and Medicare bad-debt claims keep deteriorating; if buybacks continue at large scale but per-share owner earnings instead stagnate—which would signal that capital allocation is shifting from "value-adding" to "self-anesthetizing." Any of these should force an investor to admit the judgment may be wrong.

Compared with other opportunities, my stance is also restrained. Against Fresenius Medical Care, DaVita's U.S. business is more concentrated, its cash-flow conversion more intuitive, and its buybacks more aggressive, but Fresenius has stronger vertical integration, lower net leverage, and more geographically diversified operations. Against SPY, DVA's current free-cash-flow yield and owner-earnings yield are clearly higher than the risk-free rate and the yields on most large-cap index heavyweights; but what it carries is higher industry concentration, payment concentration, and leverage risk. As for the risk-free return, the U.S. 10-year Treasury yield on May 29, 2026 was about 4.45%; DVA's current yield on conservative owner earnings is roughly 9%, so on the surface the risk premium looks decent—but that risk premium is not "free." It requires investors to truly understand the U.S. kidney-disease payment structure and to be willing to bear single-industry exposure over the long term.

If I could hold only five assets, at today's price I would not put DVA in the top five. Not because it is bad, but because within a "high-quality + high-leverage + high-policy-sensitivity" combination, I demand a higher margin of safety. If the price returned to $150-170, I would be markedly more positive.

Below is a concise checklist:

Checklist	Assessment	Brief comment
Can I understand this business	Pass	Dialysis and payment structure are understandable, but Medicare/commercial-insurance details are complex
Does it have durable, stable demand	Pass	ESRD demand is inelastic
Does it have a durable moat	Uncertain	It has scale and regulatory barriers, but the profit pool is fragile
Does it have pricing power	Fail	More like contract bargaining and rule-following than proactive price increases
Can it generate stable free cash flow	Pass	Cash flow has been strong for years
Is its return on capital excellent	Uncertain	Operating returns are not bad, but ROE/PB are distorted
Is management trustworthy	Pass	Incentives, ownership, and disclosure are generally good
Is capital allocation rational	Pass	Buybacks have long been effective, but there is an over-preference tendency
Is the balance sheet sound	Fail	Negative equity, leverage above 3x, weak hard-asset cushion
Is the valuation below intrinsic value	Uncertain	Below neutral valuation, but not clearly below the conservative value
Is the margin of safety sufficient	Fail	Not thick enough for a relatively conservative investor
Does long-term holding let me rest easy	Uncertain	The business is stable, but the payment structure is not fully reassuring
Which key facts would make me sell	Clear	Deteriorating commercial payment, rising leverage, deteriorating cash flow
Am I buying only because of price or emotion	Needs self-check	This is not an "extremely cheap" moment

The "assessment" column in the table is opinion; the brief comments are derived from the company's 10-K/10-Q and regulatory and market data.

Finally, to close in the format you requested:

【Final Rating】 Watch

【One-Sentence Investment Thesis】 DaVita is a kidney-services leader with stable demand, strong cash flow, and excellent buyback discipline, but because nearly all of its profit depends on high-priced commercial payment and its balance sheet lacks a hard safety cushion, the current price is not yet enough to give a relatively conservative investor an ample margin of safety.

【Core Bull Case】

ESRD dialysis is an inelastic, continuous, life-sustaining need, and industry demand is stable.
The industry is highly concentrated; DaVita has large scale, high regulatory barriers, and mature operating capability.
Cash-flow quality is good; for years operating cash flow has been well above net income attributable, and trailing-twelve-month free cash flow is about $1.209 billion.
Management has long allocated capital around per-share value growth, and the share count has shrunk markedly over the past few years.
Current cash-flow multiples are not high, at about 10-11x owner earnings / FCF.

【Core Bear Case】

Commercial payers account for only a small share of patients yet contribute nearly all profit; the profit pool is fragile.
The balance sheet is not sound enough: high leverage, negative equity, and a high goodwill share.
The industry lacks genuine free pricing power, and margins are squeezed by Medicare rules, commercial contracts, and cost pressure.
Although buybacks are effective, they have also raised financial fragility and introduced the mechanical-buyback factor of the Berkshire agreement.
Liquidation value is unattractive, and there is no book-asset backstop if the investment fails.

【Key Assumptions】

The commercial-payment patient share and average realized rates do not undergo a structural decline.
Net debt/EBITDA can stay around roughly 3-3.5x rather than climbing continually.
Operating-cash-flow conversion stays above or close to net income.
Regulatory adjustments are broadly mild, with no substantive restructuring of ESRD commercial-insurance treatment.
Management continues to base buybacks on cash flow and valuation discipline rather than pursuing EPS alone.

【Fair Buy Price】 $150-170/share. The basis: this is equivalent to a further 25%-35% discount to my "fair value center," while corresponding to a thicker owner-earnings yield and higher compensation for payment/leverage risk.

【Target Holding Period】 At least 5-10 years, better suited to more than 10 years. The premise is that you are willing to treat it as a long-term operating business rather than trade it on policy news or quarterly price swings.

【Expected Annualized Return】

Conservative scenario: 5%-7%
Neutral scenario: 8%-11%
Optimistic scenario: 12%-14% This is an inference based on the current owner-earnings yield, future growth of 1%-4.5%, and valuation multiples staying broadly stable or changing slightly—not a promise.

【Maximum Loss Risk】 If the commercial payment structure deteriorates and owner earnings are revised down to around $800 million, while the market assigns only a low valuation of about 8x, equity value could fall to around $6.4 billion, corresponding to about 50% downside from the current market cap; if refinancing pressure is layered on, losses could be larger. Although this is not the base-case scenario, it explains why the current price still cannot be called "high margin of safety."

【Tracking Metrics】 Track these most important items continuously: the U.S. dialysis commercial-payment patient share; the commercial-payment average realized rate; the U.S. dialysis operating margin; trailing-twelve-month free cash flow; net debt/EBITDA; interest cost; changes in receivables and contract assets; buyback price and buyback scale; U.S. dialysis treatment growth; and CMS annual rate updates and related legal/litigation developments.

【Signals That Trigger Re-evaluation】 Continued deterioration in the commercial payment structure; net leverage rising above 4x; free cash flow clearly below net income for several consecutive quarters; rapid rises in longer-aged receivables and Medicare bad-debt claims; large buybacks continuing while per-share owner earnings no longer grow; and substantive adverse changes by the regulatory or judicial environment to ESRD commercial-insurance treatment.

【Final Recommendation】 To put it calmly, DaVita is worth studying and may be worth holding for the long term, but today's price is better suited to "keep tracking and wait for a better entry point" than to have relatively conservative capital rush in. If you already understand this business and accept that it is not a "pure moat" but a composite of "high cash flow + high policy sensitivity," then DVA can stay on your long-term watch list; but if you demand a thick margin of safety, I suggest waiting patiently.

Open Questions and Limitations This report has tried to prioritize the latest 10-K, 10-Q, proxy statement, company IR, CMS, MedPAC, USRDS, and official market data; two points still bear noting. First, dialysis peers are extremely concentrated, and FMS's IFRS/ADR/exchange-rate basis is not fully comparable to DVA's, so "peer-multiple comparison" is inherently less precise than in a typical industry. Second, the historical basis for maintenance capex is disclosed at varying levels of detail across years, so I deliberately used a more conservative range for owner earnings rather than pursuing a seemingly precise single-point figure.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.

Mentioned Tickers

FMS BRK-B

Baillie Framework · Ten Questions for Growth Investing

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

How high is its market ceiling? Is it enlarging an existing pie, or creating an entirely new market?4/10

DaVita's market ceiling is not low, but its shape is closer to "share, efficiency, and payment-structure optimization within a mature large pool" than to creating an entirely new market. The core TAM is determined by the number of ESRD dialysis patients, treatment frequency, revenue per treatment, and the payer structure. This demand is very inelastic: by the end of 2025 DaVita served about 200,500 U.S. dialysis patients and operated 2,657 U.S. outpatient dialysis centers, and served about 94,500 patients across 14 overseas countries; in Q1 2026 the company further disclosed about 296,300 patients worldwide and 3,262 centers (of which 2,666 in the United States)DaVita Q1 2026. But "inelastic" does not equal "high growth": the company's Q1 U.S. dialysis normalized non-acquired treatment growth was only 0.1%, indicating that core-business treatment volume is more like low-single-digit—or even near-zero-growth—basic-healthcare traffic than a rapidly expanding consumer or technology market.

On the payment side, the ceiling is also constrained by regulated rates. About 86% of revenue comes from U.S. dialysis; within 2025 U.S. dialysis patient service revenue, government programs total 68% and commercial and hospital dialysis 32%; the company also discloses that non-hospital commercial-payment patients account for about 11% of U.S. dialysis patients yet contribute about 26% of U.S. dialysis revenue, and that commercial payers contribute nearly all profitDaVita 2025 10-K. CMS raised the 2026 ESRD PPS base rate to $281.71, expected to increase total payments to ESRD facilities by about 2.2%—more of an inflation/policy formulaic update than corporate free pricing powerCMS ESRD PPS.

So what DVA can "enlarge" is mainly the existing pie: absorbing regional centers, raising penetration of home dialysis/hospital dialysis/lab services, and using IKC and value-based care to manage more kidney-disease medical spending. IKC has some extensibility—in Q1 2026 risk-based integrated-care patients numbered about 62,600, corresponding to about $5.4 billion in annualized medical spendingDaVita Q1 2026—but it still controls costs around the existing CKD/ESRD population rather than independently opening up new demand. Peer Fresenius also had 3,539 clinics and 289,923 patients in Q1 2026, showing the industry is a globally mature duopoly competitive landscapeFresenius Q1 2026. The conclusion: the market ceiling is enough to support stable cash flow and moderate growth, but the open-ended upper bound is limited; DVA is deepening and thickening its position within the existing dialysis and kidney-care pie rather than creating an entirely new market.

Jun 8, 2026
Can its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new business?2/10

I do not treat "revenue at least doubling in five years" as DaVita's base case. Starting from 2025 consolidated revenue of $13.643 billion, doubling in five years would mean revenue reaching about $27 billion, implying a CAGR near 15%; that does not match its current core-business structure. About 86% of 2025 revenue came from the U.S. dialysis business, whose core drivers are treatment count and revenue per treatment—not a new market still penetrating rapidly. A simple sanity check is the historical trajectory: 2025 revenue grew 6.5% year over year, already including faster ancillary-services growth plus price and mix factors; even extending mid-single-digit growth for five years falls far short of doubling revenue. Absent large-scale M&A, a marked rise in commercial-insurance prices, or better-than-expected value-based-care contract expansion, doubling is more of an upside scenario than a plannable main line.

Broken down, the volume contribution is on the weak side. DaVita officially disclosed 7,029,525 U.S. dialysis treatments in Q1 2026, averaging 91,650 per day, with normalized non-acquired treatment growth of only 0.1%. This shows same-store or organic treatment volume is essentially flat, and future volume growth is more likely to come from population aging and the slow expansion of the diabetes and CKD/ESKD patient pool than from explosive new demand.

The price contribution matters more than volume, but it is not free pricing either. In Q1 2026, U.S. dialysis revenue per treatment was $417.59, higher than $400.14 in the prior-year period, showing that payment mix and unit price can bring revenue elasticity; but the Medicare ESRD PPS is a bundled payment system, and CMS's 2026 update merely raised the base rate to $281.71 and is expected to increase total payments by about 2.2%. Commercial-insurance rates and share are the key to profit elasticity, but they are also where regulatory, employer-insurance-design, and payer-negotiation risks are most concentrated.

On new business, Integrated Kidney Care, value-based care, home dialysis, and the international business can raise the revenue ceiling, but they currently look more like extensions around the core business. In 2025, ancillary services including the international business generated about $1.922 billion in revenue, only about 14% of consolidated revenue, of which the international business made up about 10% of consolidated revenue. These businesses can push the company from low-single-digit to mid-single-digit growth, but independently driving total revenue to double would require very large M&A or risk-contract expansion, for which evidence is currently insufficient. The more reasonable path is "small volume growth + mild improvement in price and payment mix + incremental contribution from peripheral businesses." Buybacks must be viewed separately: they can lift EPS, FCF/share, and per-share value, but they do not increase consolidated revenue, and buyback-driven per-share growth should not be misread as revenue doubling.

Jun 8, 2026
Five years from now, what will take the baton as the next growth engine? Does this "second curve" exist today?4/10

The growth engine most likely to take the baton in five years is a set of extensions around whole-cycle kidney-patient management: IKC/value-based care, home dialysis, and international dialysis. They all exist today, but they do not yet look like a "second curve" that could replace the core U.S. center-based dialysis business. In 2025 about 86% of DaVita's consolidated revenue still came from U.S. dialysis; the other segments, including IKC, other ancillary, and the international business, generated about $1.922 billion in combined revenue, about 14% of consolidated revenue (DaVita 2025 10-K). This shows new business is not wishful thinking, but for now it is more of a core-business extension than an independent new growth platform.

IKC/VBC is the direction most worth tracking of the three, because it pushes the company from "per-treatment dialysis" toward "managing total CKD/ESKD medical cost." As of the end of 2025, IKC covered about 66,000 risk-based integrated-care patients and 9,400 other integrated-care patients; 2025 IKC revenue was $542 million, up 7.5% year over year, with operating income of $22 million. By Q1 2026, DaVita disclosed about 62,600 risk-based integrated-care patients, corresponding to about $5.4 billion in annualized medical spending (DaVita Q1 2026). This model is already commercialized, but the profit pool is still very small, and the company also flags that VBC contracts entail bearing total medical cost, payer negotiation, and regulatory and data-system execution risk; its value is more likely to come from reducing hospitalizations, slowing disease progression, and improving payers' total cost than from rapidly scaling a revenue multiple the way a software platform would.

Home dialysis is likewise a real trend, but it remains a shift in dialysis-service form: within 2025 U.S. dialysis revenue, outpatient, home, and hospital accounted for roughly 76%, 18%, and 6% respectively, making it hard to single-handedly support a company-level reacceleration. The international business is larger in scale, with 2025 revenue of about $1.346 billion, about 10% of consolidated revenue, but with stronger foreign-exchange, local-regulatory, payment-system, and earnings volatility. Adding that Q1 2026 U.S. normalized non-acquired treatment growth was only 0.1%, the more reasonable judgment is: the second curve already has seeds and partial revenue, and within five years it is more likely to strengthen the core business's defense, raise patient-lifetime value, and slowly push the company from a "dialysis-facility operator" toward a "kidney-disease cost manager"; but it has not yet proven it can take the baton as a new core profit pool. The real validation point is not an expanding patient-count metric, but whether these businesses can contribute stable operating profit without amplifying medical-cost risk. Unless IKC grows fast for years with expanding margins, and home dialysis or the international business is no longer merely a core-business supplement, DVA's next stage remains low-single-digit growth plus per-share buyback compounding rather than a second-curve-driven reacceleration.

Jun 8, 2026
What is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

DaVita's core competitive advantage is not a brand premium, nor network effects, and certainly not free pricing power to raise prices at will; it looks more like an entry-and-execution moat. Dialysis is a highly regulated, process-heavy, locally-service-dense business, and a new entrant must simultaneously build out facilities, clinical teams, medical directors, nephrologist referral relationships, payer contracts, and compliance and billing capabilities. By the end of 2025 DaVita had 2,657 U.S. outpatient dialysis centers, about 200,500 U.S. patients, plus 585 overseas centers, and by Q1 2026 it served about 296,300 patients worldwide across 3,262 facilities, of which 2,666 in the United States. This scale brings efficiency in procurement, scheduling, back-office IT, compliance, and payment collection, and makes it harder for small players to replace it within local physician and insurance networks. Patients undergo multiple treatments per week and are sensitive to location, time slots, physician collaboration, and insurance coverage, so a degree of switching cost exists; but this cost leans toward "service continuity" rather than software-account or ecosystem-style lock-in.

But this moat must be viewed at a discount. The U.S. dialysis industry is not DaVita's alone; Fresenius remains a strong rival, disclosing in Q1 2026 3,539 dialysis clinics worldwide and 289,923 patients. More importantly, DVA's profit quality is constrained by the payment system: the company discloses that non-hospital commercial payers account for about 11% of U.S. dialysis patients yet contribute about 26% of U.S. dialysis patient service revenue, and that commercial payers contribute nearly all profit; meanwhile CMS's 2026 ESRD PPS update was a base rate of $281.71 with total payments expected to rise about 2.2%, showing the government side sets rates by rule rather than corporate free pricing.

So over the next three to five years, I lean toward saying the moat is "stable but not clearly widening," and even carries some risk of slightly narrowing under commercial-payment pressure, Medicare rules, labor costs, and the advance of new home-dialysis/value-based-care models. DVA's facility density, compliance capability, and execution processes will still keep out low-quality entrants, and demand is very inelastic; but if the commercial-insurance patient share or rates are compressed, existing scale cannot fully protect the margin. Unless IKC, home dialysis, and value-based care can upgrade the company from a "dialysis-facility operator" into a stronger kidney-disease management platform, there is limited room for the moat to deepen. In other words, its moat can protect its service-supply position but cannot fully protect the profit pool.

Jun 8, 2026
If its core business were disrupted, does it have the genes to reinvent itself? How does it treat mistakes and bad news?4/10

DaVita has some self-reinvention genes, but it looks more like the gradual reinvention of a "process-driven operating organization" than a technology company that can proactively disrupt itself. It has not bet its future on a single facility model: at the end of 2025 the company disclosed that its international business operated or managed 585 dialysis centers in 14 countries with about 94,500 patients, and IKC served 66,000 risk-based patients and 9,400 other integrated-care patients; IKC also participates in value-based-care arrangements such as CKCC, with goals including slowing kidney-disease progression and, where appropriate, promoting home dialysis and transplant incentives, all of which show it has extension moves beyond center-based dialysis. These moves look more like adapting to changes in payment and treatment models than a start-from-scratch breakout. In Q1 2026, against a backdrop of only 0.1% organic growth in U.S. dialysis treatment volume, the company still delivered $3.416 billion in revenue, $482 million in operating income, and $1.209 billion in trailing-twelve-month free cash flow, reflecting the resilience of its processes, billing, procurement, and clinical operations.

But this reinvention capability must be discounted. IKC, home dialysis, and the international business are still extensions around the core, not a proven second engine that can replace the U.S. center-based dialysis profit pool; and the company's most core vulnerability lies precisely in its payment structure. DaVita discloses that commercial-payer payments contribute nearly all profit and that all non-hospital dialysis profit comes from commercial payers, which means that if commercial-insurance rates, patient mix, or government rules are reshaped, organizational execution can only cushion, not fully offset, the impact. Its attitude toward mistakes and bad news is relatively transparent: the 10-K explicitly lists execution risks such as IKC, value-based care, home dialysis, government-payment cuts, and information-system upgrades, and discloses that the 2025 cybersecurity incident caused some PII/PHI exposure and disrupted operations and receivables collection, though patient care continued and the related business functions have been restored. This shows the company does not avoid bad news but tends to bring incidents into a framework of control, disclosure, and process repair; still, there is no evidence yet that it would proactively sacrifice short-term profit pool for long-term transformation and rapidly self-disrupt. This is a culture willing to write bad news into its risk disclosures; it also reminds investors that DaVita's "reinvention" relies more on compliance, processes, and capital discipline, with its speed and error tolerance constrained by regulation, leverage, and commercial-payment dependence.

Jun 8, 2026
Does management (especially the founder) have long-term vision, with interests deeply aligned with the company? Are they willing to sacrifice current profit for five to ten years out?5/10

My judgment: DaVita's management has a clear shareholder orientation, but it is not the typical picture of a "founder at the helm, willing to sacrifice current profit for ten years out." Public governance filings show Javier Rodriguez is a professional-manager-type CEO; as of March 31, 2026, he held 845,144 shares, about 1.3%. That is not small for a professional manager and is enough to make him care about per-share value, but it does not amount to a founder's deep alignment of staking most of his net worth on the company.

The incentive design also leans toward per-share results rather than mere scale expansion. The company's 2026 proxy statement discloses that 2025 long-term incentives consisted of 60% PSUs, 20% RSUs, and 20% SSARs, with PSUs assessed mainly on adjusted EPS and relative TSR. This has benefits: management will not open facilities inefficiently just to grow revenue, and capital allocation revolves around shareholder returns. But it also has a side effect: an EPS metric naturally encourages buybacks, which is not necessarily equivalent to a willingness to sacrifice current profit to cultivate a second curve five to ten years out.

If "long-term vision" is defined as not chasing short-term revenue and being able to invest capital where returns are higher, DaVita's management performs well; it has not expanded blindly for facility count, but has instead returned much of its mature core-business cash flow to remaining shareholders. But if the standard is raised to "willing to significantly depress current profit and heavily reinvest in new markets or platforms for years on end," the evidence is much weaker. DaVita is still investing in integrated kidney care, the international business, and operating systems, but these look more like extensions around the core dialysis business and efficiency engineering than a founder-style bet that would have the company proactively sacrifice current EPS for a huge new market ten years out.

The truly strong long-term anchor comes from Berkshire. The proxy statement discloses that Buffett and Berkshire-related entities hold 30,100,585 shares, 45.5%; and the DaVita-Berkshire buyback agreement stipulates that if Berkshire's stake reaches at least 45%, the company must repurchase enough shares each quarter to bring it back to around 45% (and avoid exceeding 49.5%)(SEC 8-K agreement). This is both external oversight and a mechanical buyback constraint.

The buyback discipline itself deserves credit: the company discloses that in Q1 2026 it repurchased 3 million shares at an average price of $133.70, and after quarter-end through May 5 it repurchased another 2 million shares at an average price of $149.81. But the cost is also clear: the 10-Q shows long-term debt of about $10.514 billion at the end of Q1 2026 and a shareholders'-equity deficit attributable to the company of about $755 million. So this is a professional-manager team with a fairly strong long-term per-share-value orientation, not unconditional long-termism; if future cash flow comes under pressure and it keeps buying back aggressively, the long-term vision would turn into a source of financial fragility.

Jun 8, 2026
If it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and free of harm to society and regulation?6/10

If DaVita disappeared tomorrow, those who would miss it most are patients and nephrologists, not payers. ESRD dialysis is not optional consumption; DaVita's 2025 10-K explains that patients with kidney failure typically need continuous dialysis or a kidney transplant to survive, and discloses that at the end of 2025 the company had about 2,657 U.S. outpatient dialysis centers serving about 200,500 U.S. dialysis patients(DaVita 2025 10-K). For patients, clinic distance, time slots, the nursing team, physician collaboration, and the insurance network are all very concrete; for nephrologists, a broadly covering, process-mature dialysis network that can steadily take in patients is also hard to replace overnight. In Q1 2026 the company disclosed U.S. dialysis treatment volume of 7,029,525, averaging 91,650 per day(DaVita Q1 2026), showing its disappearance would create a real gap in medical services, even if Fresenius and regional providers could eventually take over some capacity. This "being missed" comes more from medical capacity, care continuity, and trusted processes than from consumer brand worship; patients may not pay a premium for the brand, but they would fear interrupted time slots, longer trips, and migration of clinical records.

But "would be missed" and "growth model is inherently sustainable" are two different things. Payers most likely would not miss DaVita the way patients would; they care more about quality, coverage, compliance, and unit cost, and might even welcome lower commercial rates. CMS uses rule-based payment for the ESRD PPS, with a 2026 base rate of $281.71 and total payments expected to rise about 2.2%(CMS CY2026 ESRD PPS), which proves dialysis services have public necessity and also shows the company has no truly free pricing power. If DaVita's growth comes from clinical quality, operating efficiency, home dialysis, integrated kidney care, and reduced hospitalization spending, the social value holds up; the stronger narrative should be helping patients avoid hospitalizations and complications and lowering payers' total cost. If it mainly relies on a minority of commercial-insurance patients bearing prices far above government programs, regulatory sustainability is much weaker. The 10-K discloses that non-hospital commercial payers account for about 11% of U.S. dialysis patients yet contribute about 26% of U.S. dialysis patient service revenue, and that commercial payments contribute nearly all profit(DaVita 2025 10-K). So DaVita is a high-necessity provider but not an uncontroversially society-friendly growth platform; the most sustainable path is using scale to raise quality and cost efficiency rather than resting profit long-term on commercial-insurance cross-subsidy and regulatory gaps.

Jun 8, 2026
What are this business's unit economics (gross margin, incremental returns)? Do they improve or worsen as it scales? Where does the money it earns go?5/10

DaVita's unit economics are real, but not "light." In the core U.S. dialysis business, Q1 2026 revenue per treatment was $417.59 and patient care costs per treatment were $280.11; at a glance each treatment has a gross difference of about $137, but that is before deducting G&A, bad debt, leases, compliance, IT, and headquarters costs. In the same quarter the company's adjusted operating margin was 14.1%. This shows facility density, scheduling, procurement, payment contracts, and clinical processes can indeed convert into cash flow, but it is not a software model where adding a customer carries almost no marginal cost. Incremental returns come mainly from higher utilization at mature centers, fuller staff scheduling, and finer procurement and processes, rather than improving linearly simply by opening more facilities; a new center must also go through licensing, physician relationships, nurse staffing, and a patient ramp, so early returns lag.

As it scales, DaVita is steadier and more efficient, but the marginal economics do not automatically improve. The reason is that the revenue side is constrained by CMS bundled payment, commercial-insurance structure, and payer negotiation, while the cost side has nurse and technician wages, drugs and supplies, facility leases, renovations, equipment, and compliance spending. More critically, profit elasticity depends heavily on the mix between commercial-payment patients and government payment; if the commercial-payment share or rates decline, the efficiency gains from scale may be offset by unit-price pressure. In its Q1 release the company disclosed trailing-twelve-month operating cash flow of $2.027 billion and free cash flow of $1.209 billion; over the same period, maintenance capex of $391 million and development capex of $144 million. Maintenance capex is used to sustain capacity, including IT, dialysis-center renovations, and asset replacement; development capex is used for new centers, expansions, relocations, and hospital-contract business. This is a high-cash-flow healthcare-services network, not an asset-light platform that needs no further investment.

The money it earns is spent mainly in three places: maintaining and expanding the center network, servicing debt and interest, and then using a large share of the remaining cash for buybacks. In Q1 the company's free cash flow was $140 million while it repurchased 3 million shares at an average price of $133.70; in 2025 it repurchased 12.679 million shares for about $1.788 billion. The cost is a very tight capital structure: as of 2026Q1, long-term debt of $10.514 billion, net debt/EBITDA of 3.34x, a total equity deficit of $476 million, and a shareholders'-equity deficit attributable to the company of $755 million. So DVA's unit economics can be summarized as "high cash flow, operations-heavy, payment-constrained": scale helps it amortize costs and defend cash flow, but it is not a high-incremental-return model where the gross margin naturally expands the larger it gets.

Jun 8, 2026
For it to 5x in ten years, which conditions must hold simultaneously? Are they realistic? What expectations does today's share price imply?3/10

For DVA to 5x in ten years, the core is not "whether dialysis demand still exists" but that three multipliers must hold simultaneously: free cash flow must grow significantly, the share count must keep being compressed via low-price buybacks, and the exit valuation must not be revised down. On the valuation anchor of 2026-05-29, with the stock at about $194.36 and a market cap of about $13.39 billion, DaVita's disclosed trailing-twelve-month free cash flow was $1.209 billion, roughly 10-11x FCF. If in ten years the market still assigns only 10-11x cash flow, a 5x roughly means FCF must approach $6 billion, or, after heavy buybacks, per-share FCF must reach several times the current level. From a per-share view, the most favorable case is the company continuing to buy back in a low-valuation range so that total FCF need not fully grow fivefold; but this requires the buyback price to be low enough, leverage not to deteriorate, and regulation not to hit the profit pool—if any one condition fails, the compounding is clearly weakened.

This combination of conditions is on the demanding side. The company does have strong cash flow and a buyback tradition, repurchasing 3 million shares at an average price of $133.70 in Q1 2026; but the core business is not a high-growth arena, with DaVita's Q1-disclosed U.S. dialysis normalized non-acquired treatment growth of only 0.1% year over year. More critically, profit quality has structural constraints: the company's 2025 10-K discloses that non-hospital commercial payers account for about 11% of U.S. dialysis patients yet contribute about 26% of U.S. dialysis patient service revenue, and that commercial payers contribute nearly all profit. This means the 5x scenario also requires the commercial-payment structure not to deteriorate, regulation not to reshape the profit pool, and net leverage not to spiral out of control under buyback and refinancing pressure. If CMS, employer insurance, or commercial payers reallocate the excess profit, low-multiple cash flow would become a value trap rather than a 5x starting point.

So the realism is not zero, but it looks more like a low-probability optimistic scenario than a base-case expectation. Today's $194.36 anchor implies that the market recognizes DVA as a mature, steady-cash-flow company that can lift per-share value through buybacks, but it has not assigned it the valuation multiple of a "ten-year 5x growth stock." For the latest quote, one should re-check the StockAnalysis DVA page; but as long as the stock is still around $190, the market is broadly pricing stable cash flow plus moderate growth, not pricing the simultaneous occurrence of a multi-fold FCF expansion, the disappearance of payment risk, and a valuation re-rating. The more realistic upside case is low-to-mid-single-digit business growth layered with high-single-digit per-share buyback compounding; this can produce decent long-term returns, but it is still one stronger, more sustainable new profit engine short of a ten-year 5x.

Jun 8, 2026
Why has the market not yet realized all this? Does it not understand, look down on it, or fail to see far enough? What would become the "narrative inflection point"?3/10

The market is not entirely unaware of DaVita's cash flow and buybacks. Public quotes show DVA still trading around $190, and it is not treated as a near-bankruptcy asset; the company also discloses $3.416 billion in revenue and $140 million in free cash flow in Q1 2026, and the repurchase of 3 million shares at an average price of $133.70. All of this is easy for the market to see. So "not understanding" is not the main cause; the real issue is that the market is unwilling to price this kind of cash flow like a high-quality growth stock. It looks more like its merits are understood while a risk discount is applied.

The discount comes mainly from three layers of doubt. First, slow core-business growth: Q1 2026 U.S. dialysis normalized non-acquired treatment growth was only 0.1%, which looks more like a mature healthcare-services network than a growth stock that doubles revenue in five years, so some capital is not failing to understand it but "looking down on" the ceiling of a low-growth, heavily regulated services business. Second, the profit structure is too dependent on the U.S. payment system: in its 2025 10-K DaVita disclosed that non-hospital commercial payers account for about 11% of U.S. dialysis patients yet contribute about 26% of U.S. dialysis patient service revenue, and that commercial payment contributes nearly all profit; this makes it hard for investors to view the current margin as a risk-free perpetuity. Third, the balance sheet adds nothing to the narrative: long-running large buybacks have raised per-share value but also brought negative equity, net leverage above 3x, and a fairly high goodwill share, so the market demands extra risk compensation.

So the more accurate framing is: the market understands the buyback math and respects the cash flow, but cannot see far enough to whether the payment structure can stay stable for ten years. A real narrative inflection point requires several things to appear at once: the commercial-patient share and commercial realized unit price not deteriorating for several consecutive quarters; CMS's annual ESRD PPS updates staying mild, with no clearly adverse rules; free cash flow staying above $1 billion while net leverage falls back below 3x; buybacks remaining disciplined rather than forcing EPS by adding leverage; and IKC or value-based care contributing quantifiable profit rather than merely a core-business side story. Another possible inflection point is the market seeing commercial-payment dependence decline without cash flow collapsing, which would prove that DVA's efficiency and clinical-network value are themselves enough to support profit. Only then could the narrative switch from a "policy-sensitive cash-flow company" to a "predictable per-share compounding machine"—and it would require ongoing verification, not single-quarter data. Conversely, if commercial-payment metrics worsen, the market would not truly change the narrative even if short-term EPS looks good.

Jun 8, 2026

Ask about this report

Members can ask about this report; once answered it appears under "Reader Q&A" on this page. You can also highlight a passage in the text to ask about it directly.